Loading…
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (16)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2014 · third_quarter · Pharmacy
H.R. 460, Patients' Access to Treatments Act (McKinley) - cost sharing in a specialty drug tier H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,010,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Social Security Administration (SSA), Treasury, Dept of, White House Office
2014 · fourth_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act HR4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid, Pharmacy; and Health Care General
Client expense: $788,488 · Firm income: Not reported
2014 · fourth_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S. 867, Medicare Prescription Drug Program Integrity and Transparency Act H.R. 2960, Medicare Prescription Drug Integrity Act of 2013 H.R., Keep the Promise to Seniors Act H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid, Pharmacy; and Health Care General H.R. 4418, Expanding the Availability of Medicare Data to Medicare/Medicaid
2014 · fourth_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act HR4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid, Pharmacy; and Health Care General
Client expense: $788,488 · Firm income: Not reported
2014 · fourth_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S. 867, Medicare Prescription Drug Program Integrity and Transparency Act H.R. 2960, Medicare Prescription Drug Integrity Act of 2013 H.R., Keep the Promise to Seniors Act H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid, Pharmacy; and Health Care General H.R. 4418, Expanding the Availability of Medicare Data to Medicare/Medicaid
Government targets: Administration for Children & Families (ACF), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Client expense: $788,488 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Government targets: Administration for Children & Families (ACF), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Client expense: $788,488 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2014 · fourth_quarter · Pharmacy
Policies related to FEHBP's pharmacy benefit (HR 1367). Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market, including: EHB, grandfathering, Rx quality, eRx, PBM disclosure, MLR. Specialty pharmacy tiering restrictions (HR 460). Regulatory implementation of a pathway for the approal of biosimilars. REMs. 340b program reform. Policies placing restrictions on pharmcy benefit design. Issues regarding making prescription drugs more affordable, including: generic user fees, pedigree, biosimilars, REMs. General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act). S. 867, HR 4437, HR 4577.
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · fourth_quarter · Pharmacy
H.R. 460, Patients' Access to Treatments Act (McKinley) - cost sharing in a specialty drug tier H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs H.R. 3116, MODDERN Cures Act (Lance) - innovations in diagnostics, drug exclusivity H.R. 3742, Antibiotic Development to Advance Patient Treatment Act (Gingrey) - treatments for serious or life-threatening diseases S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,230,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office
2014 · fourth_quarter · Pharmacy
H.R. 460, Patients' Access to Treatments Act (McKinley) - cost sharing in a specialty drug tier. H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. H.R. 3116, MODDERN Cures Act (Lance) - innovations in diagnostics, drug exclusivity. H.R. 3742, Antibiotic Development to Advance Patient Treatment Act (Gingrey) - treatments for serious or life-threatening diseases. S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
H.R. 1367, FEHBP Prescription Drug Integrity Transparency and Cost Savings Act H.R. 1780, Requiring Federal Employees to Participate in Affordable Care Act Health Plans H.R. 3170, Health Care Regulator Accountability Act S. 1327, Healthy Competition for Small Business ActH.R. 3164, to clarify application of Affordable Care Act to Federal Government and Congress H.R. 3104, to clarify application of Affordable Care Act to Federal Government and Congress H.R. 3319, Equal Healthcare Access Act H.R. 779, Access to Insurance for all Americans Act
Client expense: $209,628 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Election Commission (FEC), Federal Reserve System, Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Customs & Border Protection
2014 · fourth_quarter · Government Issues
Oppose H. Con. Res. 96, Fiscal year 2015 Budget Resolution - assumes reduction of federal workforce by 10 percent and an increase in federal employee contributions toward retirement. Support H.R. 26, Deferred Benefits Adjustment Act of 2013 Oppose H.R. 249, the Federal Employee Tax Accountability Act of 2013 Support H.R. 517, a bill to provide that four of the 12 weeks of parental leave available to a federal employee shall be paid leave. Support H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. Oppose H.R. 1780, a bill that would remove federal employees from the Federal Employees Health Benefits Program (FEHBP), instead only allowing the provision of health benefits through state-based insurance exchanges. Support H.R. 1795, the Social Security Fairness Act of 2013, & S. 896, the Social Security Fairness Act of 2013. Both bills repeal both the Government Pension Offset (GPO) and the Windfall Elimination Provision (WEP). Oppose H.R. 1541, the Common Sense in Compensation Act Oppose H.R. 1660, the Government Customer Service Improvement Act Oppose H.R. 2009, Keep the IRS Off Your Health Care Oppose H.R. 2565, the Stop Targeting Our Politics IRS Act Oppose H.R. 2579, the Government Employee Accountability Act Oppose H.R. 2711, the Citizen Empowerment Act Oppose H.R. 2879, the Stop Government Abuse Act Support H.R. 3201, Pay Our Military Act Support Federal Employee Retroactive Pay Fairness Act, S. 1567/H.R. 3223. Support H.Res. 388, in support of federal employees. Support H.R. 3310, the ASSURE Act, to protect federal retirees from predatory lending practices. Support H.R. 3744, the Federal Employee Pay Restoration Act. Support H.R. 4193, Smart Savings Act. Support S. 2117, the Smart Savings Act. Support H.R. 4202, the CPI-E Act of 2014 Support H.R. 4306 and S. 2397, the FAIR Act. Support amendment to H.R. 4435, the National Defense Authorization Act of 2015, to extend authority of agencies to rehire annuitants on a limited basis without a salary offset for their annuities. Support same amendment to S. 2410. Support H.R. 4621, Federal Employee Combat Zone Tax Parity Act Support H.R. 5338, the Federal Employee Pension Fairness Act.
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Personnel Management (OPM), SENATE, U.S. Postal Service (USPS)
2014 · fourth_quarter · Health Issues
H.R.1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.H.R.517, Federal Employees Paid Parental Leave Act of 2013. S.857, Family and Medical Leave Inclusion Act.
Client expense: $70,000 · Firm income: Not reported
Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2014 · fourth_quarter · Pharmacy
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy. Issues impacting PBMs in up coming health related legislation. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in International Naming policies for generic medications. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefits. Issues regarding prescription drug coverage for the Department of Defense. Issues related to Part D coverage for Medicare Beneficiaries in Hospice Care.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $500,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · third_quarter · Government Issues
Oppose H. Con. Res. 96, Fiscal year 2015 Budget Resolution - assumes reduction of federal workforce by 10 percent and an increase in federal employee contributions toward retirementSupport H.R. 26, Deferred Benefits Adjustment Act of 2013 Oppose H.R. 249, the Federal Employee Tax Accountability Act of 2013 Support H.R. 517, a bill to provide that four of the 12 weeks of parental leave available to a federal employee shall be paid leave. Support H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. Oppose H.R. 1780, a bill that would remove federal employees from the Federal Employees Health Benefits Program (FEHBP), instead only allowing the provision of health benefits through state-based insurance exchanges. Support H.R. 1795, the Social Security Fairness Act of 2013, & S. 896, the Social Security Fairness Act of 2013. Both bills repeal both the Government Pension Offset (GPO) and the Windfall Elimination Provision (WEP). Oppose H.R. 1541, the Common Sense in Compensation Act Oppose H.R. 1660, the Government Customer Service Improvement Act Oppose H.R. 2009, Keep the IRS Off Your Health Care Oppose H.R. 2565, the Stop Targeting Our Politics IRS Act Oppose H.R. 2579, the Government Employee Accountability Act Oppose H.R. 2711, the Citizen Empowerment Act Oppose H.R. 2879, the Stop Government Abuse Act Support H.R. 3201, Pay Our Military Act Support Federal Employee Retroactive Pay Fairness Act, S. 1567/H.R. 3223. Support H.Res. 388, in support of federal employees. Support H.R. 3310, the ASSURE Act, to protect federal retirees from predatory lending practices. Support H.R. 3744, the Federal Employee Pay Restoration Act. Support H.R. 4193, Smart Savings Act. Support S. 2117, the Smart Savings Act. Support H.R. 4202, the CPI-E Act of 2014 Support H.R. 4306 and S. 2397, the FAIR Act. Support amendment to H.R. 4435, the National Defense Authorization Act of 2015, to extend authority of agencies to rehire annuitants on a limited basis without a salary offset for their annuities. Support same amendment to S. 2410. Support H.R. 4621, Federal Employee Combat Zone Tax Parity Act Support H.R. 5338, the Federal Employee Pension Fairness Act. Support issuance of regulations on phased retirement for federal employees
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Personnel Management (OPM), SENATE, U.S. Postal Service (USPS)
2014 · third_quarter · Pharmacy
H.R. 460, Patients' Access to Treatments Act (McKinley) - cost sharing in a specialty drug tier H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,010,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Social Security Administration (SSA), Treasury, Dept of, White House Office
2014 · third_quarter · Health Issues
Issues related to the corporate business model, smoking cessation, Medicare Part D and anti-PBM legislation. Other issues include health care delivery system reforms including telehealth, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. Issues related to Federal Employees Health Benefits Plan.Issues relating to the use of protected health information. HR 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act S 867-Medicare Prescription Drug Program Integrity and Transparency Act HR 3392-Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013 HR 4302 Protecting Access to Medicare Act of 2014 HR 4160 The Keep your Promise to Seniors Act HR 1024-Medication Therapy Management Empowerment Act of 2013 S 557-Medication Therapy Management Empowerment Act of 2013
Client expense: $4,290,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office
2014 · third_quarter · Pharmacy
H.R. 460, Patients' Access to Treatments Act (McKinley) - cost sharing in a specialty drug tier. H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
H.R. 1367, FEHBP Prescription Drug Integrity Transparency and Cost Savings Act H.R. 1780, Requiring Federal Employees to Participate in Affordable Care Act Health Plans H.R. 3170, Health Care Regulator Accountability Act S. 1327, Healthy Competition for Small Business ActH.R. 3164, to clarify application of Affordable Care Act to Federal Government and Congress H.R. 3104, to clarify application of Affordable Care Act to Federal Government and Congress H.R. 3319, Equal Healthcare Access Act H.R. 779, Access to Insurance for all Americans Act
Client expense: $195,530 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Election Commission (FEC), Federal Reserve System, Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Customs & Border Protection
2014 · third_quarter · Health Issues
H.R.1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.H.R.517, Federal Employees Paid Parental Leave Act of 2013. S.857, Family and Medical Leave Inclusion Act.
Client expense: $70,000 · Firm income: Not reported
Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2014 · third_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid; Pharmacy; and Health Care General H.R. 4418, Expanding the Availability of Medicare Data Act to Medicare/Medicaid
Client expense: $788,458 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2014 · third_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S.867, Medicare Prescription Drug Program Integrity and Transparency Act H.R. 2960, Medicare Prescription Drug Integrity Act of 2013 H.R. 4160, Keep the Promise to Seniors Act H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid; Pharmacy; and Health Care General H.R. 4418, Expanding the Availability of Medicare Data Act to Medicare/Medicaid
Client expense: $788,458 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2014 · third_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $500,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · third_quarter · Pharmacy
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy. Rules, regulations and guidance specific to prescription drug pricing, generic utilization, biosimilars and specialty pharmacy. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in naming policies for upcoming biosimilars. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefit. Issues regarding prescription drug coverage for public benefit programs. Issues related to Part D coverage for Medicare beneficiaries in hospice care.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · second_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · second_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid ; Pharmacy; and Health Care General H.R. 4418, Expanding the Availability of Medicare Data Act to Medicare/Medicaid
Client expense: $1,318,034 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2014 · second_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio). Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S.867, Medicare Prescription Drug Program Integrity and Transparency Act H.R. 2960, Medicare Prescription Drug Integrity Act of 2013 H.R. 4160, Keep the Promise to Seniors Act H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014 to Medicare/Medicaid ; Pharmacy; and Health Care General H.R. 4418, Expanding the Availability of Medicare Data Act to Medicare/Medicaid
Client expense: $1,318,034 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2014 · second_quarter · Government Issues
Oppose H. Con. Res. 96, Fiscal year 2015 Budget Resolution - assumes reduction of federal workforce by 10 percent and an increase in federal employee contributions toward retirementSupport H.R. 26, Deferred Benefits Adjustment Act of 2013 Oppose H.R. 249, the Federal Employee Tax Accountability Act of 2013 Support H.R. 517, a bill to provide that four of the 12 weeks of parental leave available to a federal employee shall be paid leave. Support H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. Oppose H.R. 1780, a bill that would remove federal employees from the Federal Employees Health Benefits Program (FEHBP), instead only allowing the provision of health benefits through state-based insurance exchanges. Support H.R. 1795, the Social Security Fairness Act of 2013, & S. 896, the Social Security Fairness Act of 2013. Both bills repeal both the Government Pension Offset (GPO) and the Windfall Elimination Provision (WEP). Oppose H.R. 1541, the Common Sense in Compensation Act Oppose H.R. 1660, the Government Customer Service Improvement Act Oppose H.R. 2009, Keep the IRS Off Your Health Care Oppose H.R. 2565, the Stop Targeting Our Politics IRS Act Oppose H.R. 2579, the Government Employee Accountability Act Oppose H.R. 2711, the Citizen Empowerment Act Oppose H.R. 2879, the Stop Government Abuse Act Support H.R. 3201, Pay Our Military Act Support Federal Employee Retroactive Pay Fairness Act, S. 1567/H.R. 3223. Support H.Res. 388, in support of federal employees. Support H.R. 3310, the ASSURE Act, to protect federal retirees from predatory lending practices. Support H.R. 3744, the Federal Employee Pay Restoration Act. Support H.R. 4193, Smart Savings Act. Support H.R. 4202, the CPI-E Act of 2014 Support H.R. 4306, FAIR Act. Support amendment to H.R. 4435, the National Defense Authorization Act of 2015, to extend authority of agencies to rehire annuitants on a limited basis without a salary offset for their annuities. Support H.R. 4621, Federal Employee Combat Zone Tax Parity Act Support issuance of regulations on phased retirement for federal employees
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Office of Personnel Management (OPM), SENATE
2014 · second_quarter · Health Issues
Issues related to Medicare Part D and anti-Pharmacy Benefit Manager legislation. Other issues include health care delivery system reforms, the sale of tobacco products, cost containment, medication adherence, restrictions on Pharmacy Benefit Manager cost saving tools like mail order, generics, and restrictions on Pharmacy Benefit Manager audit practices. H.R. 1367 FEHBP Prescription Drug Integrity, Transperency, and Cost Savings Act. H.R. 2810, S. 1871
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Pharmacy
H.R. 460, Patients' Access to Treatments Act (McKinley) cost sharing in a specialty drug tier16. Specific Lobbying Issues (continued): H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs H.R. 3204, Drug Quality and Security Act (Upton) drug safety issues S. 214, Preserve Access to Affordable Generics Act (Klobuchar) access to generic drugs Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,530,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Social Security Administration (SSA), Treasury, Dept of, White House Office
2014 · second_quarter · Health Issues
Issues related to the corporate business model, Medicare Part D and anti-PBM legislation. Issues related to health care delivery system reforms, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. Privacy issues relating to the use of protected health information.HR 1367, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act. Issues Related to Healthcare Reform Implementation
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
H.R. 1367, FEHBP Prescription Drug Integrity Transparency and Cost Savings Act H.R. 1780, Requiring Federal Employees to Participate in Affordable Care Act Health Plans H.R. 3170, Health Care Regulator Accountability Act S. 1327, Healthy Competition for Small Business ActH.R. 3164, to clarify application of Affordable Care Act to Federal Government and Congress H.R. 3104, to clarify application of Affordable Care Act to Federal Government and Congress H.R. 3319, Equal Healthcare Access Act H.R. 779, Access to Insurance for all Americans Act
Client expense: $199,805 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Election Commission (FEC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Customs & Border Protection
2014 · second_quarter · Pharmacy
H.R. 460, Patients' Access to Treatments Act (McKinley) - cost sharing in a specialty drug tier. H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. H.R. 3204, Drug Quality and Security Act (Upton) - drug safety issues. S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · second_quarter · Pharmacy
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail. Issues related to the practice of giving coupons for certain prescription medications.CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Focused on policies that would negatively impact access to mail order pharmacy options. President Obama's budget for FY 2015 - focused on Medicare Part D, Medicaid and OPM as that related to dispensing of Rx Regulatons pretaining to Medicare Part C&DMedicare Call Letter for Medicare PArt D bids for 2015 and its impact on access to prescripton medications and pharmacy networks. Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions. Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits. Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order. Issues related to the practice of providing coupons for prescription medications for seniors. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
H.R.1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.H.R.517, Federal Employees Paid Parental Leave Act of 2013. S.857, Family and Medical Leave Inclusion Act.
Client expense: $70,000 · Firm income: Not reported
Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2014 · second_quarter · Pharmacy
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy.Issues impacting PBMs in up coming health related legislation. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in International Naming policies for generic medications. ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefits. Issues regarding prescription drug coverage for DoD Issues related to Part D coverage for Medicare Beneficiaries in Hospice Care.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Government Issues
Oppose H. Con. Res. 25, Fiscal year 2014 Budget Resolution - assumes reduction of federal workforce by 10 percent and an increase in federal employee contributions toward retirementS. Con. Res. 8, Senate Budget Resolution Support H.R. 26, Deferred Benefits Adjustment Act of 2013 Oppose H.R. 249, the Federal Employee Tax Accountability Act of 2013 Support H.R. 517, a bill to provide that four of the 12 weeks of parental leave available to a federal employee shall be paid leave. Support H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. Oppose H.R. 1780, a bill that would remove federal employees from the Federal Employees Health Benefits Program (FEHBP), instead only allowing the provision of health benefits through state-based insurance exchanges. Support H.R. 1795, the Social Security Fairness Act of 2013, & S. 896, the Social Security Fairness Act of 2013. Both bills repeal both the Government Pension Offset (GPO) and the Windfall Elimination Provision (WEP). Oppose H.R. 1541, the Common Sense in Compensation Act Oppose H.R. 1660, the Government Customer Service Improvement Act Oppose H.R. 2009, Keep the IRS Off Your Health Care Oppose H.R. 2565, the Stop Targeting Our Politics IRS Act Oppose H.R. 2579, the Government Employee Accountability Act Oppose H.R. 2711, the Citizen Empowerment Act Oppose H.R. 2879, the Stop Government Abuse Act Support H.R. 3201, Pay Our Military Act Support Federal Employee Retroactive Pay Fairness Act, S. 1567/H.R. 3223. Support H.Res. 388, in support of federal employees. Support H.R. 3310, the ASSURE Act, to protect federal retirees from predatory lending practices. Support H.R. 3744, the Federal Employee Pay Restoration Act. Support H.R. 4193, Smart Savings Act. Support H.R. 4202, the CPI-E Act of 2014 Support H.ZR. 4306, FAIR Act.
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
Issues related to the corporate business model, smoking cessation, Medicare Part D and anti-PBM legislation. Other issues include health care delivery system reforms, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. HR 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings ActS 867-Medicare Prescription Drug Program Integrity and Transparency Act HR 3392-Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013 HR 4302 Protecting Access to Medicare Act of 2014 HR 4160 The Keep your Promise to Seniors Act HR 1024-Medication Therapy Management Empowerment Act of 2013 S 557-Medication Therapy Management Empowerment Act of 2013
Client expense: $2,950,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Treasury, Dept of
2014 · first_quarter · Health Issues
Issues related to the corporate business model, Medicare Part D and anti-Pharmacy Benefit Manager legislation. Other issues include health care delivery system reforms, the sale of tobacco products, cost containment, medication adherence, restrictions on Pharmacy Benefit Manager cost saving tools like mail order, generics, and restrictions on Pharmacy Benefit Manager audit practices. H.R. 1367 FEHBP Prescription Drug Integrity, Transperency, and Cost Savings Act. H.R. 2810, S. 1871
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
Issues related to the corporate business model, Medicare Part D and anti-PBM legislation. Issues related to health care delivery system reforms, cost containment, medication adherence, restrictions on PBM cost saving tools like mail order, generics and restrictions on PBM audit practices. Privacy issues relating to the use of protected health information.HR 1367, FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act. Issues Related to Healthcare Reform Implementation
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2014 · first_quarter · Pharmacy
H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs16. Specific Lobbying Issues (continued): H.R. 3204, Drug Quality and Security Act (Upton) drug safety issues S. 214, Preserve Access to Affordable Generics Act (Klobuchar) access to generic drugs Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation. 18. Name of Lobbyists (continued): C. Lawrence: Assistant, Legislative Director for Rep. Bill Cassidy (LA-6); May 2008-July 200: Staff Assistant, Legislative Correspondent for Rep. Tom Price (GA-6)
Client expense: $2,430,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office
2014 · first_quarter · Health Issues
H.R. 1367, FEHBP Prescription Drug Integrity Transparency and Cost Savings Act H.R. 1780, Requiring Federal Employees to Participate in Affordable Care Act Health Plans H.R. 3170, Health Care Regulator Accountability Act S. 1327, Healthy Competition for Small Business ActH.R. 3164, to clarify application of Affordable Care Act to Federal Government and Congress H.R. 3104, to clarify application of Affordable Care Act to Federal Government and Congress H.R. 3319, Equal Healthcare Access Act
Client expense: $182,841 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Federal Election Commission (FEC), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, U.S. Customs & Border Protection
2014 · first_quarter · Health Issues
H.R.1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.H.R.517, Federal Employees Paid Parental Leave Act of 2013. S.857, Family and Medical Leave Inclusion Act.
Client expense: $80,000 · Firm income: Not reported
Government targets: Federal Aviation Administration (FAA), HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2014 · first_quarter · Pharmacy
Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit design and pricing (MAC)issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding. S. 867, the Medicare Prescription Drug Program Integrity and Transparency Act.
Client expense: $650,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Personnel Management (OPM), SENATE, White House Office
2014 · first_quarter · Health Issues
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio).Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act
Client expense: $939,936 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2014 · first_quarter · Pharmacy
Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio).Regulatory and proposed legislative changes to Medicare part D including pharmacy networks, classes of clinical concern, mail-service pharmacy, EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors. Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs. Regulatory Implementation of the HITECH Act. FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs, 340B program. Issues related to the compounding of certain drugs. S. 77, Prescription Drug and Health Improvement Act S. 557, Medication Therapy Management Empowerment Act H.R. 460, Patients Access to Treatments Act H.R. 1188, Preserving Our Hometown Independent Pharmacies Act H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 1024, Medication Therapy Management Empowerment Act S.867, Medicare Prescription Drug Program Integrity and Transparency Act H.R. 2960, Medicare Prescription Drug Integrity Act of 2013 H.R. 4160, Keep the Promise to Seniors Act
Client expense: $939,936 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2014 · first_quarter · Pharmacy
H.R. 1367, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs; H.R. 3204, Drug Quality and Security Act (Upton) - drug safety issues; S. 214, Preserve Access to Affordable Generics Act (Klobuchar) - access to generic drugs.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Pharmacy
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negative impact peoples access to prescription medications through mail. Issues related to the practice of giving coupons for certain prescription medications.CMS call letter focused on changes in policies regarding mail order and pharmacy networks.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · first_quarter · Health Issues
H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Focused on policies that would negatively impact access to mail order pharmacy options. President Obama's budget for FY 2015 - focused on Medicare Part D, Medicaid and OPM as that related to dispensing of Rx Regulatons pretaining to Medicare Part C&DMedicare Call Letter for Medicare PArt D bids for 2015 and its impact on access to prescripton medications and pharmacy networks. Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions. Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits. Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order. Issues related to the practice of providing coupons for prescription medications for seniors. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Issues related to curbing opioid abuse in the Medicare and Medicaid programs.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE